Arnatar is developing ART4, an antisense oligonucleotide that ups the expression of its target protein to treat a rare ...

Thousands of employees across the Department of Health and Human Services are set to lose their collective bargaining rights ...

The FDA Adverse Event Reporting System, which Commissioner Marty Makary called “clunky,” previously published updates on a ...

Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the ...

The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and ...

VantAI will use its machine learning capabilities to identify novel target-effector pairs that Halda can use in designing its ...

Vanda claims that two generics to its sleep disorder drug Hetlioz were approved despite inadequate data and is requesting ...

While it’s impossible to make apples-to-apples comparisons of the many obesity candidates with so many differences across ...

With results from highly anticipated trials of Eli Lilly’s orforglipron and Viking Therapeutics’ VK2735 “underwhelming” ...

The FDA recommends that companies use overall survival as a primary endpoint for clinical trials where feasible. The new ...

There’s still much more to come from the White House on tariffs, but the European Union has now reached a trade agreement ...

The platform strategy of using one molecule to target an underlying biological pathway to address many different diseases can ...